Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 10, 2012, Pages 3460-3466

  Martínez González, Sonia ^a   Hernández, Ana Isabel ^a   Varela, Carmen ^a   Rodríguez Arístegui, Sonsoles ^a   Lorenzo, Milagros ^a   Rodríguez, Antonio ^a   Rivero, Virginia ^a   Martín, José Ignacio ^a   Saluste, Carl Gustav ^a   Ramos Lima, Francisco ^a   Cendón, Elena ^a   Cebrián, David ^a   Aguirre, Enara ^a   Gomez Casero, Elena ^a   Albarrán, Maribel ^a   Alfonso, Patricia ^a   García Serelde, Beatriz ^a   Oyarzabal, Julen ^a,b   Rabal, Obdulia ^a,b   Mulero, Francisca ^a   Gonzalez Granda, Teresa ^a   Link, Wolfgang ^a   Fominaya, Jesús ^a   Barbacid, Mariano ^a   Bischoff, James R ^a,c   Pizcueta, Pilar ^a   Pastor, Joaquín ^a   more..

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c JOHNSON AND JOHNSON   (United States)

Author keywords

Cancer treatment; PI3K inhibitors

Indexed keywords

ETP 46321; IMIDAZOLE DERIVATIVE; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PHOSPHATIDYLINOSITOL 3 KINASE DELTA INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN P110; PYRAZINE DERIVATIVE; SERINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER TISSUE; CONTROLLED STUDY; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; ENZYME PHOSPHORYLATION; GENE MUTATION; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TIME; TUMOR MODEL; TUMOR VOLUME;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; HUMANS; IMIDAZOLES; ISOENZYMES; PHOSPHATIDYLINOSITOL 3-KINASES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; PYRAZINES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84860467003     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2012.03.090     Document Type: Article

References (31)

1. B. Vanhaesebroeck, S.J. Leevers, K. Ahmadi, J. Timms, R. Katso, P.C. Driscoll, R. Woscholski, P.J. Parker, and M.D. Waterfield Annu. Rev. Biochem. 70 2001 535
2. L.C. Cantley Science 296 2002 1655
3. S.J. Leevers, B. Vanhaesebroeck, and M.D. Waterfield Curr. Opin. Cell Biol. 11 1999 219
4. M.A. Lawlor, and D.R. Alessi J. Cell Sci. 114 2001 2903
5. I. Vivanco, and C.L. Sawyers Nat. Rev. Cancer 2 2002 489
6. J. Domin, and M.D. Waterfield FEBS Lett. 410 1997 91
7. B. Vanhaesebroeck, and M.D. Waterfield Exp. Cell Res. 253 1999 239
8. B. Vanhaesebroeck, S.J. Leevers, G. Panayotou, and M.D. Waterfield Trends Biochem. Sci. 22 1997 267
9. D.A. Fruman, R.E. Meyers, and L.C. Cantley Annu. Rev. Biochem. 67 1998 481
10. K. Hopkins Science 282 1998 282
11. T. Maehama, and J.E. Dixon Trends Cell Biol. 9 1999 125
12. L. Simpson, and R. Parsons Exp. Cell Res. 264 2001 29
13. L. Shayesteh, Y. Lu, W.-L. Kuo, R. Baldocchi, T. Godfrey, C. Collins, D. Pinkel, B. Powell, G.B. Mills, and J.W. Gray Nat. Genet. 21 1999 99
14. Y.-Y. Ma, S.-J. Wei, Y.-C. Lin, J.-C. Lung, T.-C. Chang, J. Whang-Peng, J.M. Liu, D.-M. Yang, W.K. Yang, and C.-Y. Schen Oncogene 19 2000 2739
15. Y. Samuels, Z. Wang, A. Bardelli, N. Silliman, J. Ptak, S. Szabo, H. Yan, A. Gazdar, S.M. Powell, G.J. Riggins, J.K. Willson, S. Markowitz, K.W. Kinzler, B. Vogelstein, and V.E. Velculescu Science 304 2004 554
16. I.G. Campbell, S.E. Russell, D.Y. Choong, K.G. Montgomery, M.L. Ciavarella, C.S. Hooi, B.E. Cristiano, R.B. Pearson, and W.A. Phillips Cancer Res. 64 2004 7678
17. S. Kang, A.G. Bader, and P.K. Vogt Proc. Natl. Sci. U.S.A. 102 2005 802
18. D.W. Parsons, T.-L. Wang, Y. Samuels, A. Bardelli, J.M. Cummins, L. DeLong, N. Silliman, J. Ptak, S. Szabo, J.K. Willson, S. Markowitz, K.W. Kinzler, B. Wogelstein, C. Lengauer, and V.E. Velculescu Nature 436 2005 792
19. Martínez González, S.; Hernández, A. I.; Varela, C.; Rodríguez-Arístegui, S.; Alvarez, R.M.; García, A. B.; Lorenzo, M.; Rivero, M.V.; Oyarzabal, J.; Rabal, O.; Bischoff; J.R.; Albarrán, M.; Cebriá, A.; Alfonso, P.; Link, W.; Fominaya, J.; Pastor, J. dx.doi.org/10.1016/j.bmcl.2012.01.074.
20. T.P. Hefron, M. Berry, G. Castanedo, C. Chang, I. Chuckowree, J. Dotson, A. Folkes, J. Gunzner, J.D. Lesnick, C. Lewis, S. Mathieu, J. Nonomiya, A. Olivero, J. Pang, D. Peterson, L. Salphati, D. Sampath, S. Sideris, D.P. Sutherlin, V. Tsui, N.C. Wan, S. Wang, S. Wong, and B. Zhu Bioorg. Med. Chem. Lett. 20 2010 2408 Some references describing other PI3K inhibitors of interest are
21. D.P. Sutherlin, D. Sampath, M. Berry, G. Castanedo, Z. Chang, I. Chuckowree, J. Dotson, A. Folkes, L. Friedman, R. Goldsmith, T. Heffron, L. Lee, J. Lesnick, C. Lewis, S. Mathieu, J. Nonomiya, A. Olivero, J. Pang, W.W. Prior, S.S. Salphati, Q. Tian, Q. Tsui, V. Tsui, N.C. Wan, S. Wang, C. Wiesmann, S. Wong, and B.Y. Zhu J. Med. Chem. 53 2010 1086
22. D.P. Sutherlin, L. Bao, M. Berry, G. Castanedo, I. Chuckowree, J. Dotson, Folkes, L. Friedman, R. Goldsmith, J. Gunzer, T. Heffron, J. Lesnick, C. Lewis, S. Mathieu, J. Murray, J. Nonomiya, J. Pang, N. Pegg, W.W. Prior, L. Rouge, L. Salphati, D. Sampath, Q. Tian, V. Tsui, N.C. Wan, S. Wang, B.Q. Wei, C. Wiesmann, P. Wu, B.Y. Zhu, and A. Olivero J. Med. Chem. 54 2011 7579
23. J.C. Verheijen, K. Yu, L. Toral-Barza, I. Hollander, and A. Zask Bioorg. Med. Chem. Lett. 20 2010 375
24. M.T. Burger, M. Knapp, A. Wagman, Z.J. Ni, T. Hendrickson, G. Atallah, Y. Zhang, K. Frazier, J. Verhagen, K. Pfister, S. Ng, A. Smith, S. Bartulis, H. Merrit, M. Weismann, X. Xin, J. Haznedar, C.F. Voliva, E. Iwanowicz, and S. Pecchi ACS. Med Chem. Lett. 2 2011 34
25. M.T. Burger, S. Pecchi, A. Wagman, Z.J. Ni, M. Knapp, T. Hendrickson, G. Atallah, K. Pfister, Y. Zhang, S. Bartulis, K. Frazier, S. Ng, A. Smith, J. Verhagen, J. Haznedar, K. Huh, E. Iwanowicz, X. Xin, D. Menezes, H. Merritt, I. Lee, M. Wiesmann, S. Kaufman, K. Crawford, M. Chin, D. Bussiere, K. Shoemaker, I. Zaror, S.M. Maira, and C.F. Voliva ACS. Med Chem. Lett. 2 2011 774
26. S. Pecchi, P.A. Renhowe, C. Taylor, S. Kaufman, H. Merritt, M. Wiesmann, K.R. Shoemaker, M.S. Knapp, E. Ornelas, T.F. Hendrickson, W. Fantl, and C.F. Voliva Bioorg. Med. Chem. Lett. 20 2010 6895
27. J. Ohwada, H. Ebiike, H. Kawada, M. Tsukazaki, M. Nakamura, T. Miyazaki, K. Morikami, K. Yoshinari, M. Yoshida, O. Kondoh, S. Kuramoto, K. Ogawa, Y. Aoki, and N. Shimma Bioorg. Med. Chem. Lett. 21 2011 1767
28. The values reported are an average of two independent data points. Details of assay conditions can be found at http://www.proQinase.com. Panel of 24 kinases: AKT1, ARK5, BRAF-V600E, CK1 α 1, DYRK1A, EGF-R, FAK, FGF-R1, FLT3, IGF1-R, IKKβ, INS-R, JAK2, JNK1, KIT, MEK1, MET, MST1, PAK1, PDGFR, PIM1, PIM2, RPS6KA1, SGK1.
29. C. Guerra, N. Mijimolle, A. Dhawahir, P. Dubus, M. Barradas, M. Serrano, V. Campuzano, and M. Barbacid Cancer Cell 4 2003 111 and references cited herein.
30. E. Castellano, and J. Downward Genes Cancer 2 2011 261
31. C. Blanco-Aparicio, M. Cañamero, Y. Cecilia, B. Pequeño, O. Renner, I. Ferrer, and A. Carnero PLoS One. 5 2010 e9305